Glenmark Pharmaceuticals Limited has informed the Exchange about intimation under Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has informed the stock exchanges about the names of its Key Managerial Personnel (KMPs) who are authorised to determine the materiality of any event or information and to make disclosures to the stock exchanges as required under SEBI's Listing Regulations. The four authorised KMPs are: Glenn Saldanha (Chairman & Managing Director), Cherylann Pinto (Executive Director – Corporate Services), Anurag Mantri (Executive Director & Global Chief Financial Officer), and Harish Kuber (Company Secretary & Compliance Officer). This is a routine regulatory compliance filing dated July 1, 2025, and does not involve any change in business, operations, or financials. No monetary values or performance figures are mentioned in the document.
This is a purely administrative compliance update with no material effect on the company's business, financials, or shareholder value. It is unlikely to have any impact on the stock price.